Rafael Holdings completes Phase 3 NPC trial, targets NDA in H2 2026
Rafael Holdings has reached the last patient last visit milestone in its pivotal Phase 3 TransportNPC trial of Trappsol Cyclo (hydroxypropyl beta-cyclodextrin) for Niemann-Pick Disease Type C1, the company confirmed alongside its fiscal third-quarter financial results on 11 June 2026. The Newark, New Jersey-based biotech said it now has a clear path to submitting a New Drug Application to the US Food and Drug Administration in the second half of calendar 2026.
The milestone follows a pre-NDA meeting with the FDA, which Rafael described as reinforcing the urgency of addressing NPC1, a rare, fatal and progressive genetic disorder with no approved disease-modifying therapy in the United States. Chief Executive Howard Jonas said the company is positioned to transition Rafael Holdings into a commercial-stage entity. "Following our pre-NDA meeting with the FDA, we believe we have a clear and expedited path forward reflective of the urgency and unmet need in NPC," Jonas said.
Trial and regulatory context
NPC1 affects an estimated one in 120,000 to 150,000 live births and causes progressive neurological deterioration, typically resulting in death in early adulthood. It has orphan drug designation in the US and EU, which carries with it a priority review voucher pathway and market exclusivity incentives that could make a successful NDA commercially significant beyond the drug's relatively small addressable patient population.
Miglustat (Actelion/Janssen) is currently the only disease-area therapy approved in Europe, though it targets substrate reduction rather than cholesterol transport. Arimoclomol received a Complete Response Letter from the FDA in 2022, leaving the US unmet-need narrative intact. A successful NDA for Trappsol Cyclo would therefore enter a largely clear US regulatory field, though the company will need to present robust efficacy and safety data from the TransportNPC dataset to satisfy a likely rigorous review. The FDA's collaboration and guidance, acknowledged by Chief Operating Officer Joshua Fine, suggests the agency has maintained close oversight of trial design.
Financials
For the three months ended 30 April 2026, Rafael reported a net loss attributable to the company of $4.2 million, or $0.08 per share, compared with a net loss of $4.8 million, or $0.19 per share, in the prior-year period. The apparent improvement in loss per share largely reflects the significant expansion of the share count following the March 2025 acquisition of Cyclo Therapeutics, which increased the weighted average shares in issue from approximately 25 million to more than 51 million.
Research and development expenditure rose to $4.9 million in the quarter from $3.0 million a year earlier, reflecting the consolidation of Cyclo's spending post-acquisition. General and administrative costs fell to $2.1 million from $3.2 million, driven by reductions in payroll and stock-based compensation. Cash and equivalents stood at $30.5 million as of 30 April 2026, down from $52.8 million at the July 2025 year-end, indicating that the company will need to manage its burn rate carefully through the NDA preparation and review period.
For the nine months to 30 April 2026, the net loss attributable to Rafael widened to $20.5 million from $18.4 million in the comparable prior-year period, again principally due to the Cyclo consolidation lifting R&D costs to $16.9 million from $5.3 million.
Near-term outlook
Investors will focus on the NDA submission timeline and the content of the TransportNPC dataset when it is presented publicly. The company has not yet confirmed a target PDUFA date or indicated whether it will seek priority review, though the pre-NDA meeting language suggests accelerated designation is being pursued. With roughly $30 million in cash, Rafael's ability to fund the submission process and initial commercial preparation without additional financing is a key watch item heading into the second half of fiscal 2026.